New cardiovascular outcomes trial data from Amgen Inc. (NASDAQ: AMGN) PCSK9 inhibitor Repatha evolocumab disappointed investors, but payers are still evaluating the data and Amgen's proposed outcome-based pricing model, which could alleviate their risk.
read full article ›FOURIER outcomes data presented at the American College of Cardiology annual meeting fell short of expectations, but could increase physician demand for the PCSK9 inhibitor, making it harder for payers to say no.
read full article ›When it comes to drug pricing, one size certainly doesn’t fit all. Biopharma firms need to devise and design appropriate pricing and commercial strategies for payers, a group of customers that don’t all care about the same things and, in some cases, whose needs may be diametrically opposed.
read full article ›Some pharmaceutical companies are charging less for drugs as a new strategy amid intense criticism over pricing, reported SwissInfo.
read full article ›Amgen is seeking additional outcomes-based contracts in rheumatoid arthritis through collaboration with Inovalon/Avalere.
read full article ›While investors, media and even some payers have been touting the pricing of three recently launched drugs as sensible, it is not clear whether the lower-than-expected list prices will actually reduce costs to payers. But they are likely to result in lower co-pays for patients, which could increase access.
read full article ›Amgen's FOURIER outcomes study of Repatha supports LDL-lowering in high risk patients, but price may have to come down dramatically to spur wide use of the PCSK9 inhibitors with the subjective condition of statin intolerance.
read full article ›With BioMarin's Brineura hitting the market with a $702,000 annual price tag, recent experience for other high-priced rare disease drugs supports the theory that payers will accept high costs for ultra-rare pediatric disease therapies.
read full article ›With diabetes therapeutics adding cardiovascular risk reduction claims, Novartis’s heart failure drug Entresto could face pressure from new fronts –
read full article ›